Effects of COVID‐19 on Parkinson's disease clinical features: a community‐based case‐control study

01 August 2020
Research
Article

Roberto Cilia MD, Salvatore Bonvegna MD, Giulia Straccia MD, Golfrè Andreasi Nico MD, Antonio E. Elia MD, PhD, Luigi M. Romito MD, PhD, Grazia Devigili MD, PhD, Emanuele Cereda MD, PhD, Roberto Eleopra MD

Motor and nonmotor symptoms significantly worsened in the COVID‐19 group, requiring therapy adjustment in one‐third of cases. Clinical deterioration was explained by both infection‐related mechanisms and impaired pharmacokinetics of dopaminergic therapy. Urinary issues and fatigue were the most prominent nonmotor issues. Cognitive functions were marginally involved, while none experienced autonomic failure.

Read more in Movement Disorders 2020 Aug. Vol. 35(8); 1287-1292

doi: 10.1002/mds.28170

Effects of COVID‐19 on Parkinson's disease clinical features: a community‐based case‐control study

Roberto Cilia MD, Salvatore Bonvegna MD, Giulia Straccia MD, Golfrè Andreasi Nico MD, Antonio E. Elia MD, PhD, Luigi M. Romito MD, PhD, Grazia Devigili MD, PhD, Emanuele Cereda MD, PhD, Roberto Eleopra MD

Share this page

About Parkinson’s

Living well

About us

Our members

Get involved

Latest

Parkinson's Europe